Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 198.10M | 189.27M | 174.02M | 165.54M | 75.58M | 71.49M |
Gross Profit | 171.02M | 162.20M | 148.44M | 142.37M | 70.20M | 66.97M |
EBITDA | 36.65M | 54.26M | 51.60M | 47.54M | 18.48M | 24.06M |
Net Income | 14.88M | 11.70M | 9.23M | 9.41M | 12.90M | 16.84M |
Balance Sheet | ||||||
Total Assets | 565.96M | 543.65M | 576.98M | 568.79M | 311.60M | 115.76M |
Cash, Cash Equivalents and Short-Term Investments | 72.16M | 34.59M | 78.54M | 47.16M | 235.62M | 47.85M |
Total Debt | 35.89M | 40.15M | 86.69M | 113.08M | 1.15M | 2.02M |
Total Liabilities | 236.84M | 215.06M | 249.13M | 235.77M | 51.32M | 47.36M |
Stockholders Equity | 329.12M | 328.59M | 327.84M | 333.02M | 260.28M | 68.39M |
Cash Flow | ||||||
Free Cash Flow | 68.61M | 24.91M | 83.20M | 12.93M | 13.21M | 10.96M |
Operating Cash Flow | 69.53M | 41.86M | 98.75M | 26.96M | 23.54M | 20.67M |
Investing Cash Flow | -14.27M | -15.81M | -15.34M | -307.32M | -10.32M | -9.71M |
Financing Cash Flow | -46.99M | -70.00M | -53.28M | 91.90M | 174.55M | -10.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | £826.45M | 70.83 | 4.50% | 0.07% | 6.74% | 54.83% | |
71 Outperform | £444.43M | 62.24 | 2.93% | 126.21% | 40.66% | -55.09% | |
68 Neutral | £913.38M | 36.03 | 3.41% | 101.32% | 11.20% | -6.80% | |
66 Neutral | £1.81B | ― | -23.77% | ― | 7.97% | 12.94% | |
61 Neutral | £333.95M | 8.49 | 11.74% | ― | 38.80% | ― | |
59 Neutral | $355.92M | ― | -5.04% | ― | -1.02% | 67.70% | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% |
Craneware plc reported strong financial performance for FY25, with revenue and profitability surpassing market expectations. The company achieved a 12% increase in adjusted EBITDA and a 9% rise in revenue, driven by sales momentum and recurring revenue streams from its Trisus Platform. The partnership with Microsoft and the focus on AI development are expected to enhance market penetration, while strong cash reserves and reduced debt position Craneware well for future growth in the US healthcare market.
The most recent analyst rating on (GB:CRW) stock is a Buy with a £28.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.
Craneware plc announced that Bain Capital Private Equity is no longer pursuing a potential acquisition of the company, following a rejected proposal valuing Craneware at £26.50 per share. The board believes this offer undervalues the company and remains confident in its strategic direction, citing strong trading performance and growth in revenue and earnings. The board attributes recent share price fluctuations to broader market factors rather than company performance, reinforcing its commitment to creating shareholder value.
The most recent analyst rating on (GB:CRW) stock is a Buy with a £28.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.
Craneware plc has announced that Bain Capital Private Equity is assessing a possible offer for the company. While no formal proposal has been received, Bain Capital has until June 13, 2025, to announce its intentions. This potential offer could significantly impact Craneware’s market positioning and stakeholder interests, pending further developments.
The most recent analyst rating on (GB:CRW) stock is a Buy with a £28.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.
Craneware plc has announced a change in its major holdings, with Liontrust Investment Partners LLP adjusting its voting rights in the company. The adjustment reflects a decrease in Liontrust’s total voting rights from 10.977% to 10.1601%, indicating a strategic shift in their investment stance. This change may impact the company’s shareholder dynamics and influence future corporate decisions.
Craneware plc announced that its Chair, Will Whitehorn, purchased 1,911 Ordinary Shares, reflecting a minor increase in his stake in the company. This transaction highlights confidence in Craneware’s market position and could positively influence stakeholder perception. Additionally, the company adjusted its total voting rights following the transfer of shares to satisfy employee share options, which now stands at 35,409,802 shares with voting rights.